Related Experiment Video

Updated: Jul 5, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Monoclonal antibodies as therapeutic agents for cancer

Marion Harris1

  • 1Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia. marion.harris@ghsv.org.au

The Lancet. Oncology
|May 4, 2004
PubMed

Insights

Targeted cancer therapies, including anticancer antibodies, show promise for improving patient survival. Research presented at the 2003 American Society of Clinical Oncology (ASCO) conference highlighted positive results for bevacizumab and cetuximab.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Targeted therapies represent a significant advancement in cancer treatment.
  • Biological therapies targeting tumor-associated antigens offer hope for improved cancer survival rates.
  • The development of imatinib for chronic myeloid leukemia paved the way for new targeted treatments.

Purpose of the Study:

  • To review the progress and potential impact of targeted therapies, particularly anticancer antibodies, in oncology.
  • To highlight promising data presented at the 2003 American Society of Clinical Oncology (ASCO) conference.
  • To assess the future role of antibody-based therapies in clinical practice.

Main Methods:

  • Review of data presented at the 2003 ASCO conference.
  • Analysis of clinical trial results for antibodies like bevacizumab and cetuximab.
  • Evaluation of the current landscape of antibody-based cancer therapies in development.

Main Results:

  • Bevacizumab and cetuximab demonstrated promising results in clinical trials.
  • An improvement in survival was observed for metastatic colorectal cancer patients.
  • Positive outcomes were reported for other antibodies in various stages of clinical development.

Conclusions:

  • Anticancer antibodies hold significant potential to impact clinical oncology practice within the next decade.
  • Continued research and development of targeted therapies are crucial for advancing cancer care.
  • The findings suggest a growing role for immunotherapy in the management of various cancers.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.